Pharsight

Rytary generic

Rytary is a drug that is owned by Impax Labs Inc. The drug contains Carbidopa and Levodopa as active ingredients and was authorized for market use on January 7, 2015. Rytary is available in capsule, extended release;oral dosage forms.

When will Rytary generic be available?

Generic versions of Rytary may become available after December 26, 2028, once the final patent, held by Impax Labs Inc., expires.

Rytary uses

Rytary is used in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Moreover, it's often used as a method of providing a therapeutically effective and stable median blood plasma level of Levodopa.

Rytary patent expiration

Rytary, from Impax Labs Inc., holds a total of 9 drug patents. One of these has already expired, with the remaining patents slated to expire on December 26, 2028. Below are the details of the patent.

EPO Oppostions filed on Rytary

Rytary dosage

Want to ask something?